百济神州2026年中期财报营收32.19亿美元，经调整净利润8.20亿美元

公告速递

Sep 10

本季度信息

百济神州公布截至2026年6月30日的中期财报：营收从上年同期的24.33亿美元同比增长32.3%至32.19亿美元。报告期内，经调整净利润约为8.20亿美元，较上年同期的3.89亿美元增长111%。

财报显示，公司毛利为28.77亿美元，同比上升36.8%，主要来自产品销售额的快速提升。经调整经营利润约9.17亿美元，较上年同期的4.14亿美元增长逾一倍。期内经营活动产生的净现金流达到6.64亿美元，同比增长115.9%，公司现金流状况进一步增强。

从成本结构看，研发投入总额11.53亿美元，同比增长14.6%，占营收比重从去年同期的约41.4%下降至35.9%。销售及管理费用同比上升15.2%至11.48亿美元，占营收比重从去年同期的约41%降至35.7%，表明在全球业务快速扩张的同时整体费用率得到有效控制。

业务分项

公司核心产品保持强劲表现。其中，主打血液肿瘤领域的百悅澤（Zanubrutinib）录得销售收入约23.42亿美元，同比增长34.5%。百澤安（Tislelizumab）的销售收入也达4.35亿美元，同比增长19.2%。此外，安加维收入同比提升28.1%至1.94亿美元，倍利妥收入同比增长42.6%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1120600611"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120600611\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120600611?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-10 16:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120600611","market":"sh","top_or_hot":-1,"title":"百济神州2026年中期财报营收32.19亿美元，经调整净利润8.20亿美元","media":"公告速递","content":"<p>本季度信息</p>\n<p>百济神州公布截至2026年6月30日的中期财报：营收从上年同期的24.33亿美元同比增长32.3%至32.19亿美元。报告期内，经调整净利润约为8.20亿美元，较上年同期的3.89亿美元增长111%。</p>\n<p>财报显示，公司毛利为28.77亿美元，同比上升36.8%，主要来自产品销售额的快速提升。经调整经营利润约9.17亿美元，较上年同期的4.14亿美元增长逾一倍。期内经营活动产生的净现金流达到6.64亿美元，同比增长115.9%，公司现金流状况进一步增强。</p>\n<p>从成本结构看，研发投入总额11.53亿美元，同比增长14.6%，占营收比重从去年同期的约41.4%下降至35.9%。销售及管理费用同比上升15.2%至11.48亿美元，占营收比重从去年同期的约41%降至35.7%，表明在全球业务快速扩张的同时整体费用率得到有效控制。</p>\n<p>业务分项</p>\n<p>公司核心产品保持强劲表现。其中，主打血液肿瘤领域的百悅澤（Zanubrutinib）录得销售收入约23.42亿美元，同比增长34.5%。百澤安（Tislelizumab）的销售收入也达4.35亿美元，同比增长19.2%。此外，安加维收入同比提升28.1%至1.94亿美元，倍利妥收入同比增长42.6%。</p>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州2026年中期财报营收32.19亿美元，经调整净利润8.20亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州2026年中期财报营收32.19亿美元，经调整净利润8.20亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-09-10 16:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>本季度信息</p>\n<p>百济神州公布截至2026年6月30日的中期财报：营收从上年同期的24.33亿美元同比增长32.3%至32.19亿美元。报告期内，经调整净利润约为8.20亿美元，较上年同期的3.89亿美元增长111%。</p>\n<p>财报显示，公司毛利为28.77亿美元，同比上升36.8%，主要来自产品销售额的快速提升。经调整经营利润约9.17亿美元，较上年同期的4.14亿美元增长逾一倍。期内经营活动产生的净现金流达到6.64亿美元，同比增长115.9%，公司现金流状况进一步增强。</p>\n<p>从成本结构看，研发投入总额11.53亿美元，同比增长14.6%，占营收比重从去年同期的约41.4%下降至35.9%。销售及管理费用同比上升15.2%至11.48亿美元，占营收比重从去年同期的约41%降至35.7%，表明在全球业务快速扩张的同时整体费用率得到有效控制。</p>\n<p>业务分项</p>\n<p>公司核心产品保持强劲表现。其中，主打血液肿瘤领域的百悅澤（Zanubrutinib）录得销售收入约23.42亿美元，同比增长34.5%。百澤安（Tislelizumab）的销售收入也达4.35亿美元，同比增长19.2%。此外，安加维收入同比提升28.1%至1.94亿美元，倍利妥收入同比增长42.6%。</p>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1120600611","we_media_id":"1097772564","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120600611","pubTimestamp":1789029421,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"公告速递","introduction":"港美股公告全覆盖","home_visible":1,"id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"百济神州公布截至2026年6月30日的中期财报：营收从上年同期的24.33亿美元同比增长32.3%至32.19亿美元。报告期内，经调整净利润约为8.20亿美元，较上年同期的3.89亿美元增长111%。财报显示，公司毛利为28.77亿美元，同比上升36.8%，主要来自产品销售额的快速提升。经调整经营利润约9.17亿美元，较上年同期的4.14亿美元增长逾一倍。此外，安加维收入同比提升28.1%至1.94亿美元，倍利妥收入同比增长42.6%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06160":"百济神州"},"translate_title":"BeiGene reported revenue of $3.219 billion and adjusted net profit of $820 million in its interim financial report for 2026.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"本季度信息\n百济神州公布截至2026年6月30日的中期财报：营收从上年同期的24.33亿美元同比增长32.3%至32.19亿美元。报告期内，经调整净利润约为8.20亿美元，较上年同期的3.89亿美元增长111%。\n财报显示，公司毛利为28.77亿美元，同比上升36.8%，主要来自产品销售额的快速提升。经调整经营利润约9.17亿美元，较上年同期的4.14亿美元增长逾一倍。期内经营活动产生的净现金流达到6.64亿美元，同比增长115.9%，公司现金流状况进一步增强。\n从成本结构看，研发投入总额11.53亿美元，同比增长14.6%，占营收比重从去年同期的约41.4%下降至35.9%。销售及管理费用同比上升15.2%至11.48亿美元，占营收比重从去年同期的约41%降至35.7%，表明在全球业务快速扩张的同时整体费用率得到有效控制。\n业务分项\n公司核心产品保持强劲表现。其中，主打血液肿瘤领域的百悅澤（Zanubrutinib）录得销售收入约23.42亿美元，同比增长34.5%。百澤安（Tislelizumab）的销售收入也达4.35亿美元，同比增长19.2%。此外，安加维收入同比提升28.1%至1.94亿美元，倍利妥收入同比增长42.6%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}